For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

TNKase will be available for the treatment of acute ischemic stroke in adults, joining the Roche subsidiary’s Activase ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA ...

The usage of tenecteplase in patients with acute ischemic stroke was associated with similar effectiveness and safety ...

As a result of the approval, Genentech has the only two FDA-approved medicines to treat AIS in its portfolio, namely TNKase and Activase (alteplase). TNKase is a tissue plasminogen activator ...

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates.

The approval is based on a large multi-center non-inferiority study demonstrating that TNKase is comparable to Activase in AIS patients in terms of safety and efficacy. The AcT (Alteplase compared ...

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase ...

It is the second FDA-approved treatment for acute ischemic stroke, the other being Activase (alteplase), also manufactured by Genentech, the release said. Tenecteplase is the first acute ischemic ...

This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a 60-minute infusion. Genentech, the manufacturer of TNKase ...